GILEAD SCIENCES, INC.
GILDAPI behind this page
GILD Q1 2026 request
Playground key active
/api/financials?ticker=GILD&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 6,960 | 6,667 | +4.4% |
Show Product Lines breakouts |
|||
| AmBisome | 138 | 139 | -0.7% |
| AmBisome · Europe | 59 | 67 | -11.9% |
| AmBisome · Rest of World | 72 | 66 | +9.1% |
| AmBisome · US | 7 | 5 | +40.0% |
| Biktarvy | 3,361 | 3,150 | +6.7% |
| Biktarvy · Europe | 437 | 375 | +16.5% |
| Biktarvy · Rest of World | 352 | 301 | +16.9% |
| Biktarvy · US | 2,573 | 2,474 | +4.0% |
| Descovy | 807 | 586 | +37.7% |
| Descovy · Europe | 23 | 21 | +9.5% |
| Descovy · Rest of World | 23 | 27 | -14.8% |
| Descovy · US | 761 | 538 | +41.4% |
| Genvoya | 264 | 364 | -27.5% |
| Genvoya · Europe | 33 | 40 | -17.5% |
| Genvoya · Rest of World | 16 | 19 | -15.8% |
| Genvoya · US | 215 | 305 | -29.5% |
| Livdelzi | 133 | 40 | +232.5% |
| Livdelzi · Europe | 18 | — | — |
| Livdelzi · US | 115 | 40 | +187.5% |
| Odefsey | 221 | 281 | -21.4% |
| Odefsey · Europe | 59 | 57 | +3.5% |
| Odefsey · Rest of World | 9 | 10 | -10.0% |
| Odefsey · US | 153 | 215 | -28.8% |
| Other | 58 | 70 | -17.1% |
| Other HIV | 73 | 91 | -19.8% |
| Other HIV · Europe | 27 | 31 | -12.9% |
| Other HIV · Rest of World | 9 | 10 | -10.0% |
| Other HIV · US | 36 | 50 | -28.0% |
| Other Liver Disease | 114 | 121 | -5.8% |
| Other Liver Disease · Europe | 78 | 76 | +2.6% |
| Other Liver Disease · Rest of World | 21 | 17 | +23.5% |
| Other Liver Disease · US | 15 | 28 | -46.4% |
| Other · Europe | 8 | 9 | -11.1% |
| Other · Rest of World | 11 | 14 | -21.4% |
| Other · US | 39 | 47 | -17.0% |
| Product | 6,946 | 6,613 | +5.0% |
| Product · Europe | 1,137 | 1,073 | +6.0% |
| Product · Rest of World | 883 | 909 | -2.9% |
| Product · US | 4,926 | 4,631 | +6.4% |
| Royalty, contract and other revenues | 14 | 54 | -74.1% |
| Royalty, contract and other revenues · Europe | 8 | 11 | -27.3% |
| Royalty, contract and other revenues · Rest of World | 6 | 6 | 0.0% |
| Sofosbuvir/Velpatasvir | 283 | 346 | -18.2% |
| Sofosbuvir/Velpatasvir · Europe | 60 | 80 | -25.0% |
| Sofosbuvir/Velpatasvir · Rest of World | 82 | 99 | -17.2% |
| Sofosbuvir/Velpatasvir · US | 141 | 166 | -15.1% |
| Symtuza - Revenue share | 138 | 114 | +21.1% |
| Symtuza - Revenue share · Europe | 28 | 29 | -3.4% |
| Symtuza - Revenue share · Rest of World | 3 | 3 | 0.0% |
| Symtuza - Revenue share · US | 107 | 82 | +30.5% |
| Tecartus | 75 | 78 | -3.8% |
| Tecartus · Europe | 37 | 31 | +19.4% |
| Tecartus · Rest of World | 8 | 8 | 0.0% |
| Tecartus · US | 30 | 40 | -25.0% |
| Total Cell Therapy | 407 | 464 | -12.3% |
| Total Cell Therapy · Europe | 183 | 180 | +1.7% |
| Total Cell Therapy · Rest of World | 74 | 84 | -11.9% |
| Total Cell Therapy · US | 150 | 200 | -25.0% |
| Total HIV | 5,030 | 4,587 | +9.7% |
| Total HIV · Europe | 607 | 553 | +9.8% |
| Total HIV · Rest of World | 419 | 370 | +13.2% |
| Total HIV · US | 4,004 | 3,664 | +9.3% |
| Total Liver Disease | 767 | 758 | +1.2% |
| Total Liver Disease · Europe | 170 | 168 | +1.2% |
| Total Liver Disease · Rest of World | 235 | 256 | -8.2% |
| Total Liver Disease · US | 362 | 335 | +8.1% |
| Total Oncology | 810 | 757 | +7.0% |
| Total Oncology · Europe | 278 | 255 | +9.0% |
| Total Oncology · Rest of World | 129 | 121 | +6.6% |
| Total Oncology · US | 403 | 381 | +5.8% |
| Total Other | 196 | 209 | -6.2% |
| Total Other · Europe | 67 | 76 | -11.8% |
| Total Other · Rest of World | 83 | 81 | +2.5% |
| Total Other · US | 46 | 52 | -11.5% |
| Trodelvy | 402 | 293 | +37.2% |
| Trodelvy · Europe | 95 | 75 | +26.7% |
| Trodelvy · Rest of World | 54 | 37 | +45.9% |
| Trodelvy · US | 253 | 181 | +39.8% |
| Veklury | 144 | 302 | -52.3% |
| Veklury · Europe | 14 | 22 | -36.4% |
| Veklury · Rest of World | 18 | 82 | -78.0% |
| Veklury · US | 112 | 199 | -43.7% |
| Vemlidy | 237 | 252 | -6.0% |
| Vemlidy · Europe | 13 | 12 | +8.3% |
| Vemlidy · Rest of World | 132 | 140 | -5.7% |
| Vemlidy · US | 91 | 100 | -9.0% |
| Yescarta | 332 | 386 | -14.0% |
| Yescarta · Europe | 146 | 149 | -2.0% |
| Yescarta · Rest of World | 67 | 77 | -13.0% |
| Yescarta · US | 120 | 160 | -25.0% |
| Yeztugo | 166 | — | — |
| Yeztugo · Rest of World | 7 | — | — |
| Yeztugo · US | 158 | — | — |
Show Geography breakouts |
|||
| Europe | 1,144 | 1,084 | +5.5% |
| Rest of World | 889 | 915 | -2.8% |
| US | 4,926 | 4,668 | +5.5% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -24 | 21 | -214.3% |
| Cost of Revenue | 1,445 | 1,540 | -6.2% |
| Research And Development Expense Excluding Acquired In Process Cost | 1,372 | 1,379 | -0.5% |
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | 107 | 253 | -57.7% |
| Selling, General & Administrative | 1,451 | 1,258 | +15.3% |
Show Business Segments breakouts |
|||
| Reportable Segment | 1,451 | 1,258 | +15.3% |
Show Counterparty Name breakouts |
|||
| Gilead Foundation · Related Party | 63 | — | — |
| Total Costs & Expenses | 4,374 | 4,430 | -1.3% |
| Operating Income | 2,586 | 2,237 | +15.6% |
| Interest Expense | 240 | 260 | -7.7% |
| Non-Operating Income (Expense) | -235 | 328 | -171.6% |
Show Equity Components breakouts |
|||
| Accumulated Net Unrealized Investment Gain Loss · Reclassification Out Of Accumulated Other Comprehensive Income | -2 | — | — |
| Income Before Taxes | 2,580 | 1,649 | +56.5% |
| Income Tax Expense (Benefit) | 559 | 334 | +67.4% |
Show Equity Components breakouts |
|||
| Income tax (benefit) expense · Reclassification Out Of Accumulated Other Comprehensive Income | -3 | 3 | -200.0% |
| Net Income | 2,021 | 1,315 | +53.7% |
Show Equity Components breakouts |
|||
| Retained Earnings | 2,021 | 1,315 | +53.7% |
| EPS (Basic) | 1.63 | 1.06 | +53.8% |
| EPS (Diluted) | 1.61 | 1.04 | +54.8% |
| Wtd Avg Shares (Basic) | 1,242 | 1,246 | -0.3% |
| Wtd Avg Shares (Diluted) | 1,254 | 1,259 | -0.4% |
| Sales & Marketing (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | 898 | 753 | +19.3% |
| General & Administrative (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | 553 | 505 | +9.5% |
| Other Non-Operating Income (Expense) | 2 | -4 | +150.0% |
| Comprehensive Income | 2,060 | 1,275 | +61.6% |
| Other Comprehensive Income | 39 | -40 | +197.5% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 39 | -40 | +197.5% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax | 61 | -58 | +205.2% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 7,628 | 7,926 | -3.8% |
| Marketable Securities (Current) | 15 | — | — |
| Accounts Receivable | 4,741 | 4,388 | +8.0% |
| Inventory | 1,914 | — | — |
Show Public Utilities Inventory breakouts |
|||
| Trodelvy | 638 | — | — |
| Prepaid Expenses & Other Current Assets | 4,342 | 2,828 | +53.5% |
| Total Current Assets | 18,641 | 16,901 | +10.3% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 5,638 | 5,421 | +4.0% |
| Marketable Securities (Non-Current) | 983 | — | — |
| Goodwill | 8,314 | 8,314 | 0.0% |
| Deferred Tax Assets | 1,767 | 2,572 | -31.3% |
| Other Non-Current Assets | 4,554 | 3,871 | +17.6% |
| Total Assets | 56,278 | 56,434 | -0.3% |
| Intangible Assets | 14,082 | 16,465 | -14.5% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Hepcludex [Member] | 408 | 494 | -17.4% |
| Intangible asset – axicabtagene ciloleucel | 3,881 | 4,288 | -9.5% |
| Intangible asset – sofosbuvir | 2,097 | 2,797 | -25.0% |
| Other Intangible Assets | 400 | 510 | -21.6% |
| Trodelvy | 7,296 | 8,377 | -12.9% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 16,382 | 19,355 | -15.4% |
| Current Liabilities | |||
| Accounts Payable | 645 | 737 | -12.5% |
| Accrued Rebates | 4,118 | 4,185 | -1.6% |
| Debt Current | 1,313 | 2,806 | -53.2% |
| Other Liabilities Current | 3,399 | 4,615 | -26.3% |
| Total Current Liabilities | 9,476 | 12,344 | -23.2% |
| Current Portion of Long-Term Debt | 1,313 | — | — |
| Non-Current Liabilities | |||
| Long-Term Debt | 20,861 | — | — |
| Accrued Income Taxes Noncurrent | 918 | 819 | +12.1% |
| Deferred Tax Liabilities | 392 | 709 | -44.7% |
| Other Non-Current Liabilities | 1,200 | 1,337 | -10.2% |
| Long-Term Debt | 22,174 | — | — |
Show Debt Instrument breakouts |
|||
| 1.20% Senior Unsecured Notes Due October 2027 · Senior Notes | 749 | — | — |
| 1.65% Senior Unsecured Notes Due October 2030 · Senior Notes | 996 | — | — |
| 2.60% Senior Unsecured Notes Due October 2040 · Senior Notes | 990 | — | — |
| 2.80% Senior Unsecured Notes Due October 2050 · Senior Notes | 1,480 | — | — |
| 2.95% Senior Unsecured Notes Due March 2027 · Senior Notes | 1,249 | — | — |
| 4.00% Senior Unsecured Notes Due September 2036 · Senior Notes | 744 | — | — |
| 4.15% Senior Unsecured Notes Due March 2047 · Senior Notes | 1,731 | — | — |
| 4.50% Senior Unsecured Notes Due February 2045 · Senior Notes | 1,736 | — | — |
| 4.60% Senior Unsecured Notes Due September 2035 · Senior Notes | 994 | — | — |
| 4.75% Senior Unsecured Notes Due March 2046 · Senior Notes | 2,225 | — | — |
| 4.80% Senior Unsecured Notes Due April 2044 · Senior Notes | 1,738 | — | — |
| 4.80% Senior Unsecured Notes Due In November 2029 · Senior Notes | 747 | — | — |
| 5.10% Senior Unsecured Notes Due June 2035 · Senior Notes | 992 | — | — |
| 5.25% Senior Unsecured Notes Due October 2033 · Senior Notes | 994 | — | — |
| 5.50% Senior Unsecured Notes Due November 2054 · Senior Notes | 989 | — | — |
| 5.55% Senior Unsecured Notes Due October 2053 · Senior Notes | 989 | — | — |
| 5.60% Senior Unsecured Notes Due November 2064 · Senior Notes | 739 | — | — |
| 5.65% Senior Unsecured Notes Due December 2041 · Senior Notes | 997 | — | — |
Show Long-Term Debt Type breakouts |
|||
| Notes Payable Other Payables | 1,094 | — | — |
| Stockholders' Equity | |||
| Common Stock | 1 | 1 | 0.0% |
| Additional Paid-In Capital | 9,305 | 8,138 | +14.3% |
| Accumulated Other Comprehensive Income | 78 | 92 | -15.2% |
| Retained Earnings | 14,131 | 10,931 | +29.3% |
| Total Stockholders' Equity | 23,515 | 19,162 | +22.7% |
| Minority Interest | -84 | -84 | 0.0% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 23,431 | 19,078 | +22.8% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 18 | 38 | -52.6% |
| Accumulated Net Unrealized Investment Gain Loss | -3 | — | — |
| Accumulated Other Comprehensive Income | 78 | 92 | -15.2% |
| Accumulated Translation Adjustment | 64 | 54 | +18.5% |
| Additional Paid In Capital | 9,305 | 8,138 | +14.3% |
| Common Stock | 1 | 1 | 0.0% |
| Noncontrolling Interest | -84 | -84 | 0.0% |
| Retained Earnings | 14,131 | 10,931 | +29.3% |
| Total Liabilities & Equity | 56,278 | 56,434 | -0.3% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation | 93 | 97 | -4.1% |
| Adjustment For Amortization | 596 | 599 | -0.5% |
| Stock-Based Compensation | 218 | 209 | +4.3% |
| Deferred Income Taxes | 179 | -199 | +189.9% |
| Increase Decrease In Equity Securities Fv Ni | -142 | 426 | -133.3% |
| Other Non-Cash Items | 183 | 91 | +101.1% |
| Change in Accounts Receivable | 134 | 79 | +69.6% |
| Change in Inventory | -52 | -223 | +76.7% |
| Change in Prepaid & Other Assets | 5 | 12 | -58.3% |
| Change in Accounts Payable | -67 | -105 | +36.2% |
| Increase Decrease In Income Taxes | -29 | -552 | +94.7% |
| Increase Decrease In Accrued Liabilities | -702 | -244 | -187.7% |
| Net Cash from Operations | 2,544 | 1,757 | +44.8% |
| Investing Activities | |||
| Purchases of Investments | -525 | — | — |
| Proceeds From Sale Of Available For Sale Securities Debt | 2,520 | — | — |
| Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | 36 | — | — |
| Payments To Acquire Businesses Net Of Cash Acquired | -109 | -273 | +60.1% |
| Payments To Acquire Other Investments | -19 | -16 | -18.8% |
| Capital Expenditures | -117 | -104 | -12.5% |
| Other Investing Activities | -17 | -23 | +26.1% |
| Net Cash from Investing | 1,770 | -415 | +526.5% |
| Financing Activities | |||
| Proceeds From Issuance Of Common Stock | 166 | 252 | -34.1% |
| Share Repurchases | -419 | -730 | +42.6% |
| Debt Repayments | -2,766 | -1,762 | -57.0% |
Show Debt Instrument breakouts |
|||
| 3.65% Senior Unsecured Notes Due March 2026 · Senior Notes | -2.75 | — | — |
| Payments Of Dividends | -1,040 | -1,010 | -3.0% |
| Proceeds From Payments For Other Financing Activities | -179 | -176 | -1.7% |
| Net Cash from Financing | -4,239 | -3,426 | -23.7% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -11 | 19 | -157.9% |
| Net Change in Cash | 65 | -2,065 | +103.1% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.